Thymosin Alpha 1 (Ta1/Thymalfasin/Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone. With over 11,000 patients studied across 30+ clinical trials, it holds FDA orphan drug designations for four conditions and is approved in 35+ countries worldwide. Ta1 demonstrates exceptional safety with less than 1% serious adverse events while providing comprehensive immune system modulation.
Primary FDA-studied route with extensive clinical data. Maximum immune modulation through systemic circulation. Established dosing protocols from 35+ countries of clinical use.
Injectable Ta1 provides optimal bioavailability (90-95%) with rapid Tmax of 2 hours. Activates multiple TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function through systemic circulation.
FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence in clinical trials.
Enhances immunogenicity in elderly and hemodialysis patients with improved antibody responses to H1N1 and COVID-19 vaccines.
Restores CD4+ T-cell counts and reduces opportunistic infections in HIV patients with sustained immunological improvement.
Reduces pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 by 40-60% while maintaining balanced immune responses in COVID-19 and sepsis.
Modulates inflammatory responses in hepatitis B/C, pancreatitis, and autoimmune conditions through TLR pathway regulation.
Supports age-related thymic decline through hormone replacement therapy and enhanced T-cell production in elderly populations.
Delays age-related immune system deterioration with improved vaccine responses and reduced infection susceptibility.
Accelerates immune system recovery following major surgery or chemotherapy through lymphocyte restoration and thymic function support.
Counters stress-induced immune suppression in athletes and high-stress situations through cortisol pathway modulation.
Increases SOD and glutathose peroxidase activity providing cellular protection against oxidative damage.
Supports cellular energy metabolism and protects against age-related mitochondrial decline.
Disclaimer
These are commonly discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified healthcare provider.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard immune support | 1.6mg | 2x weekly | SubQ |
| Acute conditions (sepsis) | 1.6mg | 2x daily × 5 days, then daily | SubQ or IM |
| Cancer/hepatitis support | 1.6mg | 2x weekly | SubQ |
| Maintenance/prevention | 1.6mg | 2x weekly | SubQ |
Timing
Injectable Ta1 can be administered at any time. Maintain consistent twice-weekly schedule (e.g., Monday/Thursday or Tuesday/Friday). Rotate injection sites to prevent tissue irritation.
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
White Lyophilized Powder
Properly freeze-dried Ta1 appears as white, fluffy powder that fills most of vial bottom. Professional pharmaceutical packaging.
Clear Solution After Reconstitution
When mixed with sterile water, solution should be crystal clear with no particles, cloudiness, or precipitation.
Proper Pharmaceutical Labeling
Vials should have clear labeling with batch numbers, expiration dates, and 1.6mg dosage clearly marked.
Minor Powder Compaction
Slight compaction during shipping is acceptable if powder dissolves completely with gentle mixing.
Discolored or Collapsed Powder
Yellow, brown, or collapsed powder indicates degradation from heat exposure or moisture damage.
Persistent Cloudiness
Solution remains cloudy, contains particles, or shows precipitation after reconstitution - indicates degraded product.
Week 1-2: Initial immune system activation
Week 2-6: Enhanced immune function and reduced infection risk
Week 6-12: Maximum immunomodulatory benefits
Week 12+: Sustained immune support with continued use
Most effective for: Immune deficiencies, chronic infections, vaccine enhancement
Comprehensive review across 11,000+ patients in 30+ clinical trials showing <1% serious adverse events, establishing excellent long-term safety profile for potential clinical applications.
View Study →Study demonstrating Ta1's ability to restore immune homeostasis in lymphocytes during post-acute sequelae of SARS-CoV-2 infection with normalized T-cell populations and reduced inflammatory markers.
View Study →Clinical study showing significant reduction in pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 while maintaining balanced immune responses in coronavirus disease patients.
View Study →Randomized trial demonstrating significant mortality reduction in severe COVID-19 patients through restoration of lymphocytopenia and reversal of exhausted T cells. Primary endpoint showed dramatic improvement in survival rates.
View Study →Largest randomized controlled trial with 1,106 sepsis patients evaluating mortality benefit. While overall results were negative, subgroup analysis suggested potential benefits in specific populations.
View Study →Pilot study in 49 hospitalized COVID-19 patients with hypoxemia and lymphocytopenia showing enhanced immune recovery but mixed clinical outcomes. Completed recruitment with published safety data.
View Study →Explore high-quality research peptides, review available laboratory results, compare compounds across research categories, and choose products based on documented information.
We invite you to register to read the latest news, offers and events about our company. We promise not spam your inbox.
